OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $2.6250.

Several research analysts have recently weighed in on OPK shares. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a “strong-buy” rating in a report on Tuesday, July 8th. Zacks Research raised OPKO Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th.

OPKO Health Price Performance

OPK stock opened at $1.45 on Tuesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41. The stock’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.40. The firm has a market cap of $1.15 billion, a P/E ratio of -5.80 and a beta of 1.40. OPKO Health has a 1 year low of $1.11 and a 1 year high of $2.04.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The company had revenue of $156.80 million during the quarter, compared to analysts’ expectations of $165.74 million. During the same quarter in the prior year, the company earned ($0.01) earnings per share. The firm’s revenue was down 13.9% compared to the same quarter last year. On average, sell-side analysts expect that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average price of $1.32 per share, for a total transaction of $891,000.00. Following the completion of the purchase, the chief executive officer directly owned 214,676,448 shares in the company, valued at $283,372,911.36. The trade was a 0.32% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 49.69% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of OPK. SG Americas Securities LLC acquired a new position in shares of OPKO Health during the first quarter worth approximately $585,000. Vanguard Group Inc. raised its stake in shares of OPKO Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company’s stock worth $48,970,000 after buying an additional 293,740 shares in the last quarter. AWM Investment Company Inc. boosted its position in shares of OPKO Health by 42.3% during the 1st quarter. AWM Investment Company Inc. now owns 1,850,000 shares of the biotechnology company’s stock valued at $3,071,000 after purchasing an additional 550,000 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of OPKO Health by 94.7% in the 4th quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company’s stock worth $855,000 after purchasing an additional 282,844 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after acquiring an additional 949,671 shares during the last quarter. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.